A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) (NCT07533006)
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last approximately 48 weeks, including screening.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (7 items).
Location: Center For Dermatology Clinical Research, Inc. β Fremont, California
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Primarily "diffuse" type of AA (characterized by diffuse hair shedding)
- Are currently experiencing other forms of alopecia
- Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study
- Have received oral JAK Inhibitors in the past
- Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study
- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness
π Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
π All Participating Trial Locations (30 Sites)
- Center For Dermatology Clinical Research, Inc. β Fremont, California
- Northridge Clinical Trials β Northridge, California
- Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway β Santa Clarita, California
- Health Clinical Research, LLC β Cutler Bay, Florida
- Brigham and Women's Hospital β Boston, Massachusetts
- Revival Research Institute, LLC β Troy, Michigan
- Stracskin β Portsmouth, New Hampshire
- Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue β San Antonio, Texas
- Jordan Valley Dermatology & Research Center β South Jordan, Utah
- Kelowna Health and Memory Centre β Kelowna,
- Ryan Clinical Research Inc. β Newmarket,
- Dar Clinical Research - Ottawa - Hunt Club Road β Ottawa,
- SIMa Recherche β Verdun,
- Beijing Friendship Hospital Affiliate of Capital University β Beijing,
- Huashan Hospital, Fudan University β Shanghai,
- Shanghai Skin Disease Hospital β Shanghai,
- Tianjin Medical University General Hospital β Tianjin,
- Erasmus Medisch Centrum β Rotterdam,
- Centrum Badan Klinicznych PI-House sp. z o.o. β Gdansk,
- Diamond Clinic β Krakow,
- Dermedic Jacek Zdybski β Ostrowiec ΕwiΔtokrzyski,
- Centrum Medyczne Ginemedica β Wroclaw,
- Chung-Ang University Hospital β Dongjak-gu,
- Inha University Hospital β Incheon,
- Jeonbuk National University Hospital β Jeonju,
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.